Compare Becton Dickinson and Co (BDX) vs GE Aerospace (GE) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Becton Dickinson and Co vs GE Aerospace — how do they compare? Becton Dickinson and Co trades at $155 (market cap $41.51B), while GE Aerospace trades at $360.5 (market cap $369.06B). The key difference: GE Aerospace is far larger — about 8.9× Becton Dickinson and Co's market cap, and Becton Dickinson and Co pays the higher dividend (2.79%). Which is the better fit depends on your goals.
| BDX | GE | |
|---|---|---|
Market Cap | $41.51B | $369.06B |
Sector | Health | Industrials |
52-Week High | $185.39 | $378.68 |
52-Week Low | $135.49 | $259.00 |
Enterprise Value | $57.97B | $378.36B |
Dividend Yield | 2.79% | 0.53% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
BDX trades at $153.83, up 1.24% today, with technical indicators showing a neutral to bullish bias. The company has consistently beaten earnings estimates in recent quarters, with Q1 2026 EPS of $2.90 exceeding expectations. Revenue growth remains steady, reaching $21.84B in 2025, though net margins have compressed to 5.12%. Recent news highlights BDX's innovation in medical technology and positive analyst sentiment.
The outlook for BDX appears balanced. Upside potential exists from continued earnings beats and strategic positioning in growing healthcare segments like GLP-1 drug support equipment. However, risks include margin pressure, elevated debt levels, and cautious hospital spending. The consensus price target of $173.40 suggests moderate upside from current levels.
GE trades at $353.42, down 1.63% on the day, with a bullish technical signal supported by moving averages and oversold RSI levels near support at $351. The company has beaten earnings estimates for three consecutive quarters, with Q1 2026 EPS of $1.86 exceeding expectations, while revenue grew to $45.86 billion in 2025. Analyst sentiment is strongly positive with a consensus buy rating and $397 price target, driven by robust aerospace demand and recent defense contract wins.
The outlook remains favorable given strong order growth and strategic investments, but risks include high valuation multiples (P/E of 43.94) and debt levels. Upside is supported by earnings momentum and institutional confidence, though investors should monitor execution on backlog conversion and macroeconomic pressures on the aerospace sector.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Becton Dickinson and Co
Becton, Dickinson is the world's largest manufacturer and distributor of medical surgical products, such as needles, syringes, and sharps-disposal units. The company also manufactures diagnostic instruments and reagents, as well as flow cytometry and cell-imaging systems. BD Interventional (largely the former Bard business) accounts for 23% of revenue. International revenue accounts for 44% of the company's business.
Read more on BDX →About GE Aerospace
General Electric Company is a globally diversified technology and financial services company. The Company's products and services include aircraft engines, power generation, water processing, and household appliances to medical imaging, business and consumer financing, and industrial products.
Read more on GE →
